Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus Price Target from Analysts

Twist Bioscience Co. (NASDAQ:TWST) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $51.90.

A number of analysts have weighed in on the company. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Scotiabank raised their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Robert W. Baird upped their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday. They issued an “outperform” rating and a $60.00 target price for the company.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Robert F. Werner sold 1,448 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,787 shares of company stock valued at $4,584,508. Insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its position in Twist Bioscience by 210.2% in the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after purchasing an additional 83,287 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares in the last quarter. FMR LLC lifted its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Twist Bioscience during the third quarter worth $599,000.

Twist Bioscience Trading Up 2.0 %

Shares of TWST opened at $48.43 on Friday. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -13.45 and a beta of 1.82. The firm’s fifty day simple moving average is $45.06 and its 200-day simple moving average is $46.76. Twist Bioscience has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.